Evidence map›Paper›PMID 38185718›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2024

Donor-Derived Engineered Microvessels for Cardiovascular Risk Stratification of Patients with Kidney Failure.

Mitesh L Rathod, Wen Yih Aw, Stephanie Huang, Jingming Lu, Elizabeth L Doherty, Chloe P Whithworth, Gang Xi, Prabir Roy-Chaudhury, William J Polacheck

Open access · hybridAbstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Microphysiological Uremia Model Reveals Biophysical Potentiators of Vascular Dysfunction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mitesh L RathodJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.
Wen Yih AwJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.
Stephanie HuangJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.
Jingming LuJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.
Elizabeth L DohertyJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.
Chloe P WhithworthDepartment of Genetics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 27599, USA.
Gang XiUNC Kidney Centre, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Prabir Roy-ChaudhuryUNC Kidney Centre, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
William J PolacheckJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill and Raleigh, NC, 27599, 27695, USA.ORCID 0000-0003-2728-0746
University of North Carolina at Chapel Hill · US

Funding

Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
RENAL EPIDEMIOLOGY TRAINING PROGRAMT32DK007750 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FALK, RONALD J · 1999 to 2022
$5.5M
Modulation of VSMC phenotype through the Insulin Receptor Substrate-1/Kruppel-like factor-4 signal transduction pathway: a Novel Target for AVF DysfunctionR01DK132328 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PRABIR ROY-CHAUDHURY, Gang Xi · 2022 to 2026
$2.7M
Integrative Approaches for the Study of the Fluidic Cellular MicroenvironmentR35GM142944 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI William J Polacheck · 2021 to 2026
$2.3M
Defining the role of extracellular matrix mechanics in vascular Ehlers-Danlos syndromeF31HL162462 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOHERTY, ELIZABETH LOUISE · 2022 to 2023
$73k
American Heart Association CDA857738American Heart Association-American Stroke Association 857738CLOVES Syndrome CommunityLymphatic Malformation InstituteNational Institutes of Health through the Integrative Vascular Biology Training Program T32HL69768National Nanotechnology Coordinated InfrastructureNational Science FoundationNHLBI NIH HHS F31 HL162462NHLBI NIH HHS F31HL162462NHLBI NIH HHS T32 HL069768NIDDK NIH HHS R01 DK132328NIDDK NIH HHS T32 DK007750NIDDK NIH HHS T32DK007750NIGMS NIH HHS R35 GM142944NIGMS NIH HHS R35 GM142944-01North Carolina Biotechnology Center 2021-FLG-3814North Carolina Research Triangle Nanotechnology Network
6 · The paper itself

Abstract

Cardiovascular disease is the cause of death in ≈50% of hemodialysis patients. Accumulation of uremic solutes in systemic circulation is thought to be a key driver of the endothelial dysfunction that underlies elevated cardiovascular events. A challenge in understanding the mechanisms relating chronic kidney disease to cardiovascular disease is the lack of in vitro models that allow screening of the effects of the uremic environment on the endothelium. Here, a method is described for microfabrication of human blood vessels from donor cells and perfused with donor serum. The resulting donor-derived microvessels are used to quantify vascular permeability, a hallmark of endothelial dysfunction, in response to serum spiked with pathophysiological levels of indoxyl sulfate, and in response to serum from patients with chronic kidney disease and from uremic pigs. The uremic environment has pronounced effects on microvascular integrity as demonstrated by irregular cell-cell junctions and increased permeability in comparison to cell culture media and healthy serum. Moreover, the engineered microvessels demonstrate an increase in sensitivity compared to traditional 2D assays. Thus, the devices and the methods presented here have the potential to be utilized to risk stratify and to direct personalized treatments for patients with chronic kidney disease.

Indexed as

Cardiovascular DiseasesMicrovesselsAnimalsHumansIndicanRenal InsufficiencyRisk AssessmentSwineTissue DonorsTissue EngineeringIndicanblood‐derived endothelial cellcardiovascularchronic kidney diseaseindoxyl sulfatemicrofluidicsorgans‐on‐chipuremic toxin

Identifiers

PMID38185718
PMCPMC11168887
OpenAlexW4390656196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.